Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 291.29K | Year: 2007
DESCRIPTION (provided by applicant): The aim of this research SBIR application is to develop a paradigm shift in diagnostic testing for a globally important, yet poorly diagnosed, healthcare-associated infectious disease, namely Clostridium difficile-associated diarrhea, or CDAD. Current laboratory testing for CDAD is limited to detection of the organism and/or its toxin product(s) and does not differentiate infected from simply colonized patients, thus leading to inaccurate diagnosis as well as antibiotic miss/overuse. To overcome these limitations, an ultra-sensitive assay that detects both microbial and host response targets for CDAD will be developed using Nanosphere's bio-barcode assay technology. In phase I, protein and DNA-based Bio-barcode assays that target toxin B (microbial target) and tropomyosin (host-response) will be developed along with protocols for stool specimen preparation. The feasibility of this new approach will be established by testing for CDAD in stool samples. In phase II, the assays will be further optimized to maximize sensitivity and specificity, and instrumentation and software will be optimized to provide a stand-alone 'kit' format that is rapid (complete testing from specimen receipt to a final result in well under 4 hours), reliable (with sensitivity and specificity greater than 95%), easy to use (so that accredited laboratories can perform the assay), and cost efficient. Clostridium difficile-associated diarrhea, or CDAD, is a globally important, yet poorly diagnosed, healthcare-associated infectious disease. Importantly, the causative agent of this disease has become a crucial emerging pathogen with new virulent strains seen in the hospital, apparent emergence of community acquired disease and recognition of CDAD as a key pathogen for HIV-infected persons. A more specific and sensitive diagnostic platform will improve patient care by enabling specific, correct treatment at a very early time point, thus lowering the potential risk of severe disease and death as well as lower the overuse of antimicrobial agents.
News Article | September 18, 2013
Nanosphere (NSDQ:NSPH) pulled down $30.2 million in a public offering of some 17.3 million shares, including a substantial over-allotment snapped up by the offering’s underwriters. The $1.75-per-share offering closed today, with underwriters Piper Jaffray & Co., Canaccord Genuity Inc. and Cowen & Co. purchasing the nearly 2.3 million-share over-allotment, Northbrook, Ill.-based Nanosphere said. Net proceeds of $27.7 million are slated for "general corporate purposes and working capital," according to a press release. Nanosphere makes molecular diagnostics devices, including the Verigene system, which uses gold nanoparticles to detect pathogens and drug-resistant marker by mapping bacterial genomes, the company said.
News Article | July 28, 2015
ABINGDON, England--(BUSINESS WIRE)--GlySure Limited, a leader in continuous glucose monitoring for critical care patients, today announced the appointment of Roger Moody as Chief Executive Officer. Mr. Moody, who has served as the Company’s Chief Operating Officer since February 2015, brings extensive experience leading emerging healthcare and technology companies through the transition from development stage to rapidly growing commercial enterprise. “GlySure is in a critical phase of growth, having just received CE mark for its continuous glucose monitor for critical care patients,” said William Moffitt, Chairman of GlySure. “The Company is on the verge of demonstrating the value of this technology to the market and we are pleased to have Roger leading this opportunity.” The GlySure System is the world’s first and only intravascular sensor that continuously monitors glucose levels for critical care patients. Numerous clinical studies over the past two decades have shown the medical and economic importance of maintaining effective control of blood sugar levels in critically ill patients. The GlySure System uniquely meets the needs of this market. “GlySure is well positioned to be the leader in building this $5 billion market, and I am honored to be part of this opportunity as we enter the commercial growth phase of our business,” said Moody. “The GlySure System is the product of years of research and development by a highly innovative team of engineers and scientists who have developed a product that addresses the market needs for continuous measurement and fits into the routine of bedside care in the ICU.” Mr. Moody has previously served in senior management roles at Nanosphere, Medsn (now Indegene) and other emerging healthcare and technology companies. GlySure is leading the way toward improved glycaemic control with the world’s first CE-marked intravascular continuous glucose monitor (CGM). The Company is enabling critical care physicians to provide enhanced glycaemic control, which has been shown to improve patient outcomes, reduce risk to patients and reduce costs. The Company has demonstrated through ICU testing that its highly accurate GlySure System provides continuous glucose readings throughout the length of a patient’s stay in the ICU. The worldwide market opportunity for the GlySure System is greater than $5 billion. For more information, visit www.glysure.com.
Nanosphere | Date: 2010-08-09
An apparatus and method for imaging metallic nanoparticles is provided. Preferably, the invention provides for an apparatus and method for detection of gold colloid particles and for accurate reporting to the operator. The apparatus includes a substrate holder for holding the substrate, a processor and memory device, an imaging module, an illumination module, a power module, an input module, and an output module. The apparatus may have a stationary substrate holder and imaging module which are proximate to one another. The apparatus provided for a compact sized system without the need for complex motorized devices to move the camera across the substrate. Further, the apparatus and method provide for automatic detection of the spots/wells on the substrate, automatic quantification of the spots on the substrate, and automatic interpretation of the spots based on decision statistics.
Nanosphere | Date: 2012-12-18
The invention relates to methods for detecting complexes of Tau, Tau variants, including phosphorylated variants, and amyloid containing molecules, as well as autoantibodies to those complexes or components of those complexes, in physiological fluid samples.